Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and preventing inflammation
Inflammation is a balanced physiological response – the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases. To help keep tabs on inflammation, immune cells employ a molecular machine called the NLRP3 inflammasome. NLRP3 is inactive in a healthy cell, but is switched “on” when the cell’s mitochondria (energy-generating organelles) are damaged by stress or exposure to bacterial toxins.
However, when the NLRP3 inflammasome gets stuck in the “on” position, it can contribute to a number of chronic inflammatory conditions, including gout, osteoarthritis, fatty liver disease and Alzheimer’s and Parkinson’s diseases. In a new mouse study, researchers at University of California San Diego School of Medicine discovered a unique approach that might help treat some chronic inflammatory diseases: force cells to eliminate damaged mitochondria before they activate the NLRP3 inflammasome.
The study, published April 11, 2019 by Cell Metabolism, was led by senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology and Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases at UC San Diego School of Medicine, and first author Elsa Sanchez-Lopez, PhD, a senior postdoctoral researcher in Karin’s lab.
In a 2018 study published in Nature, Karin’s team had shown that damaged mitochondria activate the NLRP3 inflammasome. The researchers also found that the NLRP3 inflammasome is de-activated when mitochondria are removed by the cell’s internal waste recycling process, called mitophagy.
“After that, we wondered if we could reduce harmful excess inflammation by intentionally inducing mitophagy, which would eliminate damaged mitochondria and should in turn pre-emptively inhibit NLRP3 inflammasome activation,” Karin said. “But at the time we didn’t have a good way to induce mitophagy.”
More recently, Sanchez-Lopez was studying how macrophages regulate their uptake of choline, a nutrient critical for metabolism, when she discovered something that can initiate mitophagy: an inhibitor of the enzyme choline kinase (ChoK). With ChoK inhibited, choline is no longer incorporated into mitochondrial membranes. As a result, the cells perceive the mitochondria as damaged, and cleared them away by mitophagy.
“Most importantly, by getting rid of damaged mitochondria with ChoK inhibitors, we were finally able to inhibit NLRP3 inflammasome activation,” Karin said.
To test their new ability to control NLRP3 inflammasome in a living system, the researchers turned to mice. They discovered that treatment with ChoK inhibitors prevented acute inflammation caused by uric acid (accumulation of which triggers gout flares) and a bacterial toxin.
By several measures, ChoK inhibitor treatment also reversed chronic inflammation associated with a genetic disease called Muckle-Well Syndrome, which is caused by mutations in NLRP3 genes. One such measure is spleen size – the larger the spleen, the more inflammation. The spleens of Muckle-Well Syndrome mice are on average twice as large as normal mice, but their spleen sizes normalized after ChoK inhibitor treatment.
NLRP3 inflammasome promotes inflammation because it triggers the release of two very potent pro-inflammatory molecules called cytokines: interleukin (IL)-1? and IL-18. According to Karin, there are existing drugs that can block IL-1?, but not IL-18. ChoK inhibitors, his team found, can reduce both cytokines.
“There are several diseases, including lupus and osteoarthritis, whose treatment will likely require dual inhibition of both IL-1? and IL-18,” Karin said.
Learn more: In Mice, Eliminating Damaged Mitochondria Alleviates Chronic Inflammatory Disease
The Latest on: Chronic inflammatory disease
[google_news title=”” keyword=”chronic inflammatory disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Chronic inflammatory disease
- Prime Medicine’s preclinical data from PM359 shows correct causative mutation of chronic granulomatous diseaseon May 11, 2024 at 1:59 am
Prime Medicine’s preclinical data from PM359 shows correct causative mutation of chronic granulomatous disease: Cambridge, Massachusetts Saturday, May 11, 2024, 14:30 Hrs [IST] ...
- First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Monthon May 9, 2024 at 6:00 am
Celiac disease is a topical issue at the forefront of many people’s lives,” said James Sapirstein, Chairman and Chief Executive Officer of First Wave BioPharma. “Often overlooked is the lack of ...
- Why Obstetric History Matters When Assessing CV Risk in Women With Autoimmune Diseaseon May 9, 2024 at 3:26 am
A history of pregnancy complications can put women with autoimmune disease at a higher risk for CVD. Prophylaxis during pregnancy may avoid those complications in the first place.
- Managing Comorbidities in Chronic Urticariaon May 8, 2024 at 9:00 pm
The link between chronic urticaria and atopic diseases, autoimmune diseases, and psychiatric disorders has significant implications for clinical practice. Managing comorbidities is key to optimizing ...
- 7 Worst Inflammatory Foods Doctors Say Make Weight Loss 'So Much Harder': Sugary Condiments & Moreon May 7, 2024 at 11:30 am
Certain foods are notorious for their inflammatory properties, potentially making weight management more challenging and increasing the risk of chronic diseases. These “worst inflammatory foods” often ...
- Crohn's Disease Newson May 3, 2024 at 5:01 pm
Though the two have similar symptoms, they require different ... July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide.
- What is the association between cytokines and autoimmune diseases?on May 3, 2024 at 8:01 am
Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system homeostasis. When the immune system malfunctions, irregularities in cytokine ...
- Boehringer Ingelheim’s Cyltezo to treat multiple chronic inflammatory diseases gets US FDA approvalon May 2, 2024 at 10:30 pm
Boehringer Ingelheim’s Cyltezo to treat multiple chronic inflammatory diseases gets US FDA approval: Ridgefield, Connecticut Friday, May 3, 2024, 11:00 Hrs [IST] Boehringer Inge ...
- How to stick to a fitness routine when you’re dealing with a chronic illnesson May 1, 2024 at 12:15 am
When you live with a chronic disease, it means dealing with an ever-present stream of stressors that other people don’t even think about, like regular doctor’s appointments, hard-to-handle symptoms, ...
- Is Ozempic the New Anti-Inflammatory Wonder Drug?on April 30, 2024 at 4:00 am
Some GLP-1s are now FDA approved for chronic weight management, including Wegovy (semaglutide) and Saxenda (liraglutide), while others like Ozempic (semaglutide) are approved for type 2 diabetes but ...
via Bing News